Introduction: Being one of the few existing measures of primary care functions, physician-level continuity of care (Phy-CoC) is measured by the weighted average of patient continuity scores. Compared with the well-researched patient-level continuity, Phy-CoC is a new instrument with limited evidence from Medicare beneficiaries. This study aimed to expand the patient sample to include patients of all ages and all types of insurance and reassess the associations between full panel-based Phy-CoC scores and patient outcomes.
Methods: Cross-sectional analysis at patient-level using Virginia All-Payer Claims Database (VA-APCD). Phy-CoC scores were calculated by averaging patient's Bice-Boxerman Index scores and weighted by the total number of visits. Patient outcomes included total cost and preventable hospitalization.
Results: In a sample of 1.6 million Virginians, patients who lived in rural areas or had Medicare as primary insurance were more likely to be attributed to physicians with the highest Phy-CoC scores. Across all adult patient populations, we found that being attributed to physicians with higher Phy-CoC was associated with 7%-11.8% higher total costs, but was not associated with the odds of preventable hospitalization. Results from models with interactions revealed nuanced associations between Phy-CoC and total cost with patient's age and comorbidity, insurance payer, and the specialty of their physician.
Conclusions: In this comprehensive examination of Phy-CoC using all populations from the VA-APCD, we found an overall positive association of higher full panel-based Phy-CoC with total cost, but a non-significant association with the risk of preventable hospitalization. Achieving higher full panel-based Phy-CoC may have unintended cost implications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3122/jabfm.2023.230119R1 | DOI Listing |
Mol Vis
January 2024
Department of Ophthalmology and Visual Sciences, University of British Columbia, Canada.
Purpose: Autosomal recessive cone and cone-rod dystrophies (CD/CRD) are inherited forms of vison loss. Here, we report on and correlate the clinical phenotypes with the underlying genetic mutations.
Methods: Clinical information was collected from subjects, including a family history with a chart review.
Cells
December 2023
Life Science Technologies, imec, B-3001 Leuven, Belgium.
Among cancer diagnoses in women, ovarian cancer has the fifth-highest mortality rate. Current treatments are unsatisfactory, and new therapies are highly needed. Immunotherapies show great promise but have not reached their full potential in ovarian cancer patients.
View Article and Find Full Text PDFJ Am Board Fam Med
January 2024
From the American Board of Family Medicine (MD, ZJM, LEP, AWB); Virginia Health Information (KR); Virginia Center for Health Innovation (BAB); Department of Family and Community Medicine at the University of Kentucky (LEP); Center for Professionalism and Value in Health Care (AWB).
Introduction: Being one of the few existing measures of primary care functions, physician-level continuity of care (Phy-CoC) is measured by the weighted average of patient continuity scores. Compared with the well-researched patient-level continuity, Phy-CoC is a new instrument with limited evidence from Medicare beneficiaries. This study aimed to expand the patient sample to include patients of all ages and all types of insurance and reassess the associations between full panel-based Phy-CoC scores and patient outcomes.
View Article and Find Full Text PDFCan J Ophthalmol
October 2024
Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC.. Electronic address:
Objective: To evaluate the success of diagnostic genetic testing in inherited retinal dystrophy (IRD) patients in the clinical setting.
Design: Retrospective cohort analysis.
Participants: A total of 446 consecutive participants from diverse ethnic backgrounds living in western Canada.
Cancer Res Commun
March 2023
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Background: Tumor mutational burden (TMB) has been investigated as a biomarker for immune checkpoint blockade (ICB) therapy. Increasingly, TMB is being estimated with gene panel-based assays (as opposed to full exome sequencing) and different gene panels cover overlapping but distinct genomic coordinates, making comparisons across panels difficult. Previous studies have suggested that standardization and calibration to exome-derived TMB be done for each panel to ensure comparability.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!